Portola Pharma (PTLA) Tops Q3 EPS by 5c

Portola Pharma (NASDAQ: PTLA) reported Q3 EPS of ($1.41), $0.05 better than the analyst estimate of ($1.46). Revenue for the quarter came in at $3.83 million versus the consensus estimate of $4.71 million.

For earnings history and earnings-related data on Portola Pharma (PTLA) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• HeartCore Enterprises, Inc. (HTCR) Misses Q2 EPS by 185c
• Neumora Therapeutics, Inc. (NMRA) Tops Q2 EPS by 4c